Zacks Research Comments on IQVIA’s Q4 Earnings (NYSE:IQV)

IQVIA Holdings Inc. (NYSE:IQV) – Zacks Research raised their Q4 2025 earnings per share estimates for shares of IQVIA in a note issued to investors on Tuesday, February 25th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $3.05 per share for the quarter, up from their previous estimate of $2.86. The consensus estimate for IQVIA’s current full-year earnings is $10.84 per share. Zacks Research also issued estimates for IQVIA’s Q3 2026 earnings at $3.24 EPS.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%.

A number of other analysts have also issued reports on the company. The Goldman Sachs Group lowered their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Morgan Stanley increased their price target on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Deutsche Bank Aktiengesellschaft decreased their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Leerink Partners reissued an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, Stephens began coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $251.22.

IQVIA Trading Down 0.1 %

NYSE IQV opened at $190.77 on Thursday. The stock has a market cap of $33.59 billion, a PE ratio of 25.44, a PEG ratio of 1.99 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The company’s 50-day moving average price is $199.40 and its 200-day moving average price is $215.46.

Insiders Place Their Bets

In related news, Director John G. Danhakl acquired 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is owned by insiders.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Forum Financial Management LP lifted its holdings in shares of IQVIA by 53.2% during the fourth quarter. Forum Financial Management LP now owns 2,067 shares of the medical research company’s stock worth $406,000 after purchasing an additional 718 shares during the period. Toronto Dominion Bank increased its holdings in shares of IQVIA by 2.2% during the 4th quarter. Toronto Dominion Bank now owns 61,774 shares of the medical research company’s stock valued at $12,139,000 after purchasing an additional 1,358 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of IQVIA in the 4th quarter valued at $841,000. WCG Wealth Advisors LLC grew its position in IQVIA by 1.7% during the fourth quarter. WCG Wealth Advisors LLC now owns 17,449 shares of the medical research company’s stock valued at $3,429,000 after buying an additional 292 shares during the period. Finally, Vega Investment Solutions purchased a new position in IQVIA in the fourth quarter valued at $976,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.